The Upstate Global Health Institute is currently seeking participants who have a history of prior well-defined or probable Lyme disease infection and meet the definition of Post-Treatment Lyme disease Syndrome (PTLDS). This research is being done to see if using an FDA approved drug, Cefriaxone, for Lyme disease is safe and well-tolerated on a 5-day dosing schedule.